Syndax Pharmaceuticals Stock Z Score

SNDX Stock

USD 16.09 0.49 3.14%

Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out Syndax Pharmaceuticals Piotroski F Score and Syndax Pharmaceuticals Valuation analysis.

For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

At this time, Syndax Pharmaceuticals' Change In Working Capital is fairly stable compared to the past year. Total Debt To Capitalization is likely to rise to 0.04 in 2024, whereas Capital Surpluse is likely to drop slightly above 669.6 M in 2024. At this time, Syndax Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 241.5 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 11.4 K in 2024.

Syndax Pharmaceuticals Company Z Score Analysis

Syndax Pharmaceuticals' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Z Score

Sum Of

5 Factors

More About Z Score | All Equity Analysis

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Syndax Z Score Driver Correlations

Understanding the fundamental principles of building solid financial models for Syndax Pharmaceuticals is extremely important. It helps to project a fair market value of Syndax Stock properly, considering its historical fundamentals such as Z Score. Since Syndax Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Syndax Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Syndax Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Net Tangible Assets	Long Term Debt	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Property Plant Equipment	Capital Surpluse	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock	Long Term Debt Total
Total Assets		1.0	0.9	-0.93	-0.93	0.88	0.94	0.63	1.0	-0.64	0.98	0.96	0.59	0.6	0.73	0.61	0.78	0.88	0.9	0.72	0.9	0.94	0.89
Total Stockholder Equity	1.0		0.9	-0.93	-0.92	0.87	0.95	0.6	1.0	-0.65	0.98	0.95	0.58	0.62	0.72	0.6	0.78	0.88	0.91	0.71	0.9	0.94	0.89
Current Deferred Revenue	0.9	0.9		-0.82	-0.81	0.82	0.86	0.44	0.89	-0.47	0.88	0.82	0.4	0.68	0.52	0.37	0.84	0.72	0.81	0.85	0.81	0.85	0.92
Net Debt	-0.93	-0.93	-0.82		0.88	-0.92	-0.77	-0.65	-0.93	0.61	-0.91	-0.88	-0.53	-0.3	-0.69	-0.57	-0.72	-0.8	-0.81	-0.79	-0.8	-0.85	-0.91
Retained Earnings	-0.93	-0.92	-0.81	0.88		-0.91	-0.88	-0.66	-0.93	0.72	-0.95	-0.94	-0.71	-0.55	-0.88	-0.77	-0.88	-0.84	-0.76	-0.65	-0.76	-0.88	-0.81
Accounts Payable	0.88	0.87	0.82	-0.92	-0.91		0.74	0.62	0.87	-0.64	0.9	0.86	0.57	0.35	0.75	0.6	0.89	0.73	0.69	0.78	0.68	0.81	0.85
Short Term Investments	0.94	0.95	0.86	-0.77	-0.88	0.74		0.53	0.95	-0.64	0.93	0.92	0.6	0.81	0.71	0.62	0.75	0.87	0.89	0.55	0.89	0.92	0.78
Total Liab	0.63	0.6	0.44	-0.65	-0.66	0.62	0.53		0.63	-0.19	0.65	0.66	0.62	0.17	0.62	0.59	0.47	0.74	0.64	0.42	0.63	0.68	0.62
Total Current Assets	1.0	1.0	0.89	-0.93	-0.93	0.87	0.95	0.63		-0.65	0.98	0.96	0.59	0.6	0.74	0.61	0.77	0.89	0.9	0.7	0.9	0.94	0.89
Short Term Debt	-0.64	-0.65	-0.47	0.61	0.72	-0.64	-0.64	-0.19	-0.65		-0.65	-0.6	-0.42	-0.39	-0.6	-0.68	-0.59	-0.6	-0.53	-0.3	-0.53	-0.62	-0.48
Common Stock	0.98	0.98	0.88	-0.91	-0.95	0.9	0.93	0.65	0.98	-0.65		0.97	0.65	0.6	0.77	0.6	0.83	0.9	0.88	0.68	0.88	0.96	0.87
Net Tangible Assets	0.96	0.95	0.82	-0.88	-0.94	0.86	0.92	0.66	0.96	-0.6	0.97		0.78	0.59	0.86	0.65	0.8	0.88	0.84	0.61	0.84	0.91	0.82
Long Term Debt	0.59	0.58	0.4	-0.53	-0.71	0.57	0.6	0.62	0.59	-0.42	0.65	0.78		0.42	0.88	0.71	0.59	0.72	0.56	0.18	0.55	0.63	0.5
Net Receivables	0.6	0.62	0.68	-0.3	-0.55	0.35	0.81	0.17	0.6	-0.39	0.6	0.59	0.42		0.4	0.38	0.59	0.61	0.66	0.26	0.66	0.66	0.51
Deferred Long Term Liab	0.73	0.72	0.52	-0.69	-0.88	0.75	0.71	0.62	0.74	-0.6	0.77	0.86	0.88	0.4		0.85	0.74	0.69	0.53	0.37	0.52	0.65	0.54
Short Long Term Debt	0.61	0.6	0.37	-0.57	-0.77	0.6	0.62	0.59	0.61	-0.68	0.6	0.65	0.71	0.38	0.85		0.59	0.63	0.48	0.24	0.48	0.56	0.47
Property Plant Equipment	0.78	0.78	0.84	-0.72	-0.88	0.89	0.75	0.47	0.77	-0.59	0.83	0.8	0.59	0.59	0.74	0.59		0.65	0.59	0.7	0.58	0.74	0.76
Capital Surpluse	0.88	0.88	0.72	-0.8	-0.84	0.73	0.87	0.74	0.89	-0.6	0.9	0.88	0.72	0.61	0.69	0.63	0.65		0.94	0.44	0.94	0.97	0.82
Net Invested Capital	0.9	0.91	0.81	-0.81	-0.76	0.69	0.89	0.64	0.9	-0.53	0.88	0.84	0.56	0.66	0.53	0.48	0.59	0.94		0.56	1.0	0.96	0.88
Long Term Investments	0.72	0.71	0.85	-0.79	-0.65	0.78	0.55	0.42	0.7	-0.3	0.68	0.61	0.18	0.26	0.37	0.24	0.7	0.44	0.56		0.54	0.59	0.83
Net Working Capital	0.9	0.9	0.81	-0.8	-0.76	0.68	0.89	0.63	0.9	-0.53	0.88	0.84	0.55	0.66	0.52	0.48	0.58	0.94	1.0	0.54		0.96	0.87
Capital Stock	0.94	0.94	0.85	-0.85	-0.88	0.81	0.92	0.68	0.94	-0.62	0.96	0.91	0.63	0.66	0.65	0.56	0.74	0.97	0.96	0.59	0.96		0.89
Long Term Debt Total	0.89	0.89	0.92	-0.91	-0.81	0.85	0.78	0.62	0.89	-0.48	0.87	0.82	0.5	0.51	0.54	0.47	0.76	0.82	0.88	0.83	0.87	0.89

Click cells to compare fundamentals

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Competition

Predict Syndax Pharmaceuticals

Based on the company's disclosures, Syndax Pharmaceuticals has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.

Syndax Pharmaceuticals Current Valuation Drivers

We derive many important indicators used in calculating different scores of Syndax Pharmaceuticals from analyzing Syndax Pharmaceuticals' financial statements. These drivers represent accounts that assess Syndax Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Syndax Pharmaceuticals' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	267.7M	918.7M	1.1B	1.5B	1.5B	1.6B
Enterprise Value	244.0M	824.0M	938.7M	1.5B	1.2B	1.3B

Syndax Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Syndax Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Syndax Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Syndax Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Syndax Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Syndax Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Syndax Pharmaceuticals' value.

		Shares
Geode Capital Management, Llc	2024-06-30	1.9 M
Marshall Wace Asset Management Ltd	2024-06-30	1.8 M
Stempoint Capital Lp	2024-09-30	1.7 M
Franklin Resources Inc	2024-06-30	1.6 M
Woodline Partners Lp	2024-06-30	1.5 M
Morgan Stanley - Brokerage Accounts	2024-06-30	1.5 M
Goldman Sachs Group Inc	2024-06-30	1.4 M
First Turn Management Llc	2024-09-30	1.2 M
Millennium Management Llc	2024-06-30	1.1 M
Blackrock Inc	2024-06-30	7.9 M
Wellington Management Company Llp	2024-06-30	7.3 M

Syndax Fundamentals

	Return On Equity	-0.82
	Return On Asset	-0.49
	Operating Margin	(7.17) %
	Current Valuation	926.04 M
	Shares Outstanding	85.36 M
	Shares Owned By Insiders	0.81 %
	Shares Owned By Institutions	99.19 %
	Number Of Shares Shorted	10.66 M
	Price To Earning	126.11 X
	Price To Book	3.63 X
	Price To Sales	83.22 X
	Gross Profit	139.71 M
	EBITDA	(229.94 M)
	Net Income	(209.36 M)
	Cash And Equivalents	350.71 M
	Cash Per Share	5.82 X
	Total Debt	1.64 M
	Debt To Equity	0 %
	Current Ratio	17.19 X
	Book Value Per Share	4.28 X
	Cash Flow From Operations	(160.6 M)
	Short Ratio	14.84 X
	Earnings Per Share	(3.64) X
	Target Price	37.29
	Number Of Employees	184
	Beta	0.92
	Market Capitalization	1.33 B
	Total Asset	612.88 M
	Retained Earnings	(902.4 M)
	Working Capital	522.78 M
	Current Asset	79.72 M
	Current Liabilities	13.32 M
	Net Asset	612.88 M

About Syndax Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Syndax Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Syndax Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Syndax Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Syndax Pharmaceuticals Stock Z Score

Syndax Pharmaceuticals Company Z Score Analysis

Z Score

Sum Of

5 Factors

First Factor

1.2 * (

Working Capital

/

Total Assets )

Second Factor

1.4 * (

Retained Earnings

/

Total Assets )

Thrid Factor

3.3 * (

EBITAD

/

Total Assets )

Fouth Factor

0.6 * (

Market Value of Equity

/

Total Liabilities )

Fifth Factor

0.99 * (

Revenue

/

Total Assets )

Syndax Z Score Driver Correlations

Syndax Pharmaceuticals Current Valuation Drivers

Syndax Pharmaceuticals ESG Sustainability

Syndax Pharmaceuticals Institutional Holders

Syndax Fundamentals

About Syndax Pharmaceuticals Fundamental Analysis

Also Currently Popular

Additional Tools for Syndax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY